Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma

9Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma. © 2014 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Makimoto, G., Fujiwara, K., Watanabe, H., Kameyama, N., Matsushita, M., Rai, K., … Shibayama, T. (2014). Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. Case Reports in Oncology, 7(1), 14–17. https://doi.org/10.1159/000357938

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free